4.9.1 Dopaminergic drugs used in Parkinson's disease
Sudden onset of sleep: Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa, co-beneldopa, and the dopamine receptor agonists. Patients starting on treatment with these drugs should be warned of the possibility of these effects and of the need to exercise caution when driving or operating machinery. Patients who have suffered excessive sedation or sudden onset of sleep, should refrain from driving or operating machines, until those effects have stopped
Please see website: Ergot-derived dopamine receptor agonists
All initiations must take place in secondary care under the direct supervision of the Parkinsons' specialist nurse
Patients must be stabilised on domperidone for at least two days before starting apormorphine treatment
| Pack |
|---|
| 5 ampoule |
For intermittent subcutaneous injection
| Pack |
|---|
| 5 pre-filled disposable injection |
For continuous subcutaneous infusion in the community
| Pack |
|---|
| 5 pre-filled disposable injection |
| Pack |
|---|
| 5 ampoule |
| Pack |
|---|
| 100 capsule |
| Pack |
|---|
| 100 capsule |
| Pack |
|---|
| 100 capsule |
| Pack |
|---|
| 100 capsule |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 90 tablet |
Sinemet Plus equivalent
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
Half Sinemet CR equivalent
| Pack |
|---|
| 100 tablet |
Sinimet CR equivalent
| Pack |
|---|
| 60 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 100 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 21 tablet |
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 84 tablet |
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 84 tablet |
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 28 patch |
| Pack |
|---|
| 28 patch |
| Pack |
|---|
| 28 patch |
| Pack |
|---|
| 28 patch |
| Pack |
|---|
| 28 patch |
| Pack |
|---|
| 28 patch |
| Pack |
|---|
| 56 tablet |
| Pack |
|---|
| 28 tablet |
1.25mg of selegiline oral lyophilisate is approximately therapeutically equivalent to 10mg selegiline tablets
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 200 ml |
- Approved as an option for use in patients who are not suitable for first line agents in the class.
- Either selegiline or rasagiline must be trialled initially unless contraindicated before prescribing safinamide.
- Specialist initiation, supply and stabilisation is required before transfer to primary care.
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 30 tablet |
Tolcapone is associated with potentially life-threatening hepatotoxicity hence regular monitoring of liver function is necessary
| Pack |
|---|
| 100 tablet |
- First Line Drugs
- Second Line Drugs
- Specialist Initiated or Recommended Drugs
- Specialist Initiated Drugs with Shared Care Guidelines
- Specialist Only Drugs
- Mixed Status